Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s stock price was down 3.3% during trading on Wednesday. The company traded as low as $1.45 and last traded at $1.45. Approximately 343,495 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.50.
Qualigen Therapeutics Stock Down 18.5%
The firm has a market capitalization of $1.80 million, a P/E ratio of -0.14 and a beta of 0.24. The business’s 50 day moving average is $1.09 and its 200-day moving average is $1.16.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc is a clinical-stage biotechnology company focused primarily on developing therapies for cancer and other serious diseases. The company’s lead therapeutic program is QN-302, a small-molecule drug candidate being investigated for its potential to treat solid tumors, including pancreatic cancer.
Qualigen is also developing additional oncology-focused programs, including QN-247, an aptamer-based candidate designed to target nucleolin, a protein associated with cancer-cell growth and survival.
Recommended Stories
- Five stocks we like better than Qualigen Therapeutics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
